Market Newsdesk

VANCOUVER, British Columbia, Nov. 23, 2020 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE:SHRC) (FSE:IWIA) (OTCQB:INTWF) (the “Company” or “SHARC Energy”) has been selected to be part of a Canadian government Clean Tech Accelerator program that will market Canada’s leading clean-technology companies to global markets.

Only nine Canadian companies were selected for a five-month Canadian Technology Accelerator (“CTA”) program, which will focus on business opportunities in Southeast Asia through a series of virtual meetings.

Led by the Canadian Trade Office in Singapore, the CTA program allows chosen companies to access potential investments, pilot projects, partnerships and long-term sales in Singapore, Vietnam, Malaysia, and the Philippines, four of the ten Association of Southeast Asian Nations (“ASEAN”) countries.

According to a report published by the International Energy Agency (“IEA”), the ASEAN region is one of the world’s hottest areas, which caused a demand growth for space cooling of 7.5 times over the last 30 years. The temperature in this region keeps rising, as well as household income, leading to an increase in energy consumption and peak electricity demand. By 2040, cooling will account for 30% of peak electricity demand in ASEAN countries, and an additional 200 GW energy capacity will be required to meet the growing energy demand from ACs. These market trends support the adoption of high-efficient cooling technologies, making SHARC Systems a good fit. Our SHARC Systems can provide a super-efficient and climate-friendly district cooling solution through wastewater thermal energy exchange, and a process called heat rejection, as well as district heating and hot water production.

“We are honoured to have been chosen by the Canadian Technology Accelerator to bring our technology to global markets,” said Hanspaul Pannu, SHARC Energy’s CFO. “By recovering or rejecting the thermal energy from the wastewater we send down the drain every day, our made-in-Canada technology will have a significant role in reducing a building’s energy costs and its carbon footprint.”

SHARC Energy’s wastewater energy recovery technology — which exchanges the thermal energy from wastewater that is sent down the drain and turns it into heating and cooling — is already being used in Canada, the United States, Australia and the United Kingdom. Designed for both individual buildings and district energy systems, SHARC Energy’s technology is highly scalable and is being applied to both new and retrofitted buildings. “The nine companies taking part in the Southeast Asia program clearly demonstrate Canada’s leadership position in the cleantech sectors,” said Tegan Watson, Trade Commissioner, Canadian Technology Accelerator, Singapore. “It’s an exciting time to showcase Canadian innovation and know-how.”

Since 2013, the CTA program has supported the international scale-up of high-growth, high-potential Canadian firms in the sectors of cleantech, as well as life sciences and digital and information communication technologies. To date the CTA program has had 574 participants, collectively garnering $646 million in capital, $238 million in revenue and created 1,128 strategic partnerships and 2,529 new jobs.

“We’re seeing significant growth in the Southeast Asian cleantech sector and that includes growth in demand for circular economy and energy efficiency technologies,” said Lynn McDonald, Canadian High Commissioner in Singapore. “There’s a great opportunity for Canadian innovation to address some of the region’s most pressing environmental issues.”

The CTA program has also partnered with industry-leading organizations at the forefront of cleantech innovation. The nine companies in this year’s program will benefit from the expertise of New Energy Nexus, SecondMuse and the EcoLabs Centre of Innovation for Energy. New Energy Nexus is an international non-profit that supports clean energy entrepreneurs with funds, accelerators, and networks. SecondMuse is an impact and innovation company that builds resilient economies by supporting entrepreneurs and the ecosystems around them. The EcoLabs Centre of Innovation for Energy is designed to build and accelerate deep-tech energy innovation capabilities in Singapore to support the nation’s energy transition.

About SHARC International Systems

SHARC International Systems Inc. is a world leader in thermal heat recovery. SHARC systems recycle thermal energy from wastewater, generating one of the most energy efficient and economical systems for heating, cooling & hot water preheating for commercial, residential and industrial buildings, reducing their carbon footprint. SHARC is publicly traded in Canada (CSE: SHRC), the United States (OTCQB: INTWF) and Germany (Frankfurt: IWIA).

Further information about the Company is available on our website at www.SHARCenergy.com or SEDAR at www.sedar.com.

ON BEHALF OF THE BOARD

“Lynn Mueller”

Chairman and Chief Executive Officer

For
investor inquiries
, please contact:

Jason Shepherd
Investor Relations
SHARC International Systems Inc.
Telephone: (250) 212-2122
Email: [email protected]

For media inquiries, please contact

Mike Tanyi
Director of Marketing and IT 
SHARC International Systems Inc. 
Telephone: (250) 212-2122 
Email: [email protected]

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. SHARC
Energy
‘s actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. SHARC
Energy
believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/87efcf37-a84a-4b02-8720-740680631c09

NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four options to commercial licenses for Teneobio human heavy chain only domain antibodies, UniDabs®, to develop novel CAR T therapies. Poseida will apply licensed UniDab binders, which possess significant advantages over traditional single chain variable antibody fragment (scFv) binders, to develop its next generation CAR-T therapies. Targets were not disclosed.

This announcement follows the expansion of a commercial license agreement between the companies that was announced in August of 2018. Under the terms of that agreement, Teneobio would generate multiple UniDab product candidates using its proprietary UniRat® transgenic human antibody ‘heavy-chain only’ rodent platform and its state-of-the-art sequence-based discovery engine, TeneoSeek. Poseida would have exclusive global licensing rights for the clinical development and commercialization of specific UniDabs for CAR cell therapies.

Teneobio Inc. receives commercial licensing fees for these milestones and is eligible to receive future research, development and regulatory milestone payments per UniDab candidate, with total potential earnings of over $250 million for CAR-T therapies developed by Poseida. Teneobio would also receive royalties on worldwide net sales of each CAR-T therapy.

“We are excited that Poseida has exercised multiple commercial license options on UniDabs to create the next generation of cell therapies,” said Omid Vafa, CBO of Teneobio. “UniDabs have been preclinically and clinically validated as excellent human single domain antibody targeting moieties of CAR T-cells. They have demonstrated both in vivo specificity and robust efficacy. Their advantageous smaller in size, and superior developability relative to standard scFv’s make them ideal for CAR T-cell products.”

Eric Ostertag, CEO of Poseida, added, “We have evaluated a large number of binding technologies for use in our CAR-T platforms and view single domain antibodies as one of the most superior. In our view, the fact that Teneobio’s VH binders are fully human makes them a better option than camelid VHH single domain antibodies.”

About Teneobio, Inc.

Teneobio, Inc. is a clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb^®), for the treatments of cancer, autoimmunity, and infectious diseases. Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat^® and OmniFlic^®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDab^®) derived from UniAb^® can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. Teneobio’s “plug-and-play” T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity.

Teneobio partners include AbbVie, Janssen, GSK, Kite, Poseida, Intellia, and ArsenalBio.  For more information, please visit www.teneobio.com.

Company Inquiries for Teneobio, Inc.

Omid Vafa, Chief Business Officer
[email protected]

WORCESTER, Mass. and MUNICH, Germany, Nov. 23, 2020 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, today announced that they have signed an agreement to enable technology transfer and GMP clinical manufacturing of Mustang’s MB-107 lentiviral gene therapy program for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease, in Europe.

Under the terms of the agreement, Minaris will perform technology transfer of the manufacturing and analytical processes, as well as their adoption to the European regulatory environment, for the GMP-compliant manufacturing of the drug product at its site in Ottobrunn, Germany, with the goal of supplying clinical trials in Europe.

“We look forward to a productive and successful partnership with Mustang where Minaris will be able to support them with our extensive experience in the clinical and commercial manufacturing of autologous gene therapies,” said Dusan Kosijer, Managing Director of Minaris. “We are eager to work together with Mustang in the fight against this devastating disease.”

“This agreement with Minaris is an important step in supporting expansion of our MB-107 pivotal clinical trial into Europe,” said Manuel Litchman, M.D., President and Chief Executive Officer of Mustang. “We look forward to working with Minaris to grow our geographic footprint and bring this potential life-saving therapy to XSCID patients in need internationally.”

MB-107 is currently being assessed in a Phase 1/2 clinical trial for XSCID in newly diagnosed infants under the age of two at St. Jude Children’s Research Hospital, UCSF Benioff Children’s Hospital in San Francisco and Seattle Children’s Hospital. Mustang submitted an investigational new drug application (“IND”) to the FDA to initiate a pivotal multi-center Phase 2 clinical trial of MB-107 in this same patient population. The trial is expected to enroll 10 patients who, together with 15 patients enrolled in the current multi-center trial led by St. Jude, will be compared with 25 matched historical control patients who have undergone hematopoietic stem cell transplantation. The primary efficacy endpoint will be event-free survival. The initiation of this trial is expected soon. Mustang is targeting topline data from this trial in the second half of 2022.

The FDA granted Rare Pediatric Disease, Orphan Drug and Regenerative Medicine Advanced Therapy Designations to MB-107 for the treatment of XSCID in newly diagnosed infants.

About X-linked Severe Combined Immunodeficiency (“XSCID”)

X-linked severe combined immunodeficiency is a rare genetic disorder that occurs in approximately 1 per 225,000 births. It is characterized by the absence or lack of function of key immune cells, resulting in a severely compromised immune system and death by one year of age if untreated. Patients with XSCID have no T-cells or natural killer cells. Although their B-cells are normal in number, they are not functional. As a result, XSCID patients are usually affected by severe bacterial, viral or fungal infections early in life and often present with interstitial lung disease, chronic diarrhea and failure to thrive.

The specific genetic disorder that causes XSCID is a mutation in the gene coding for the common gamma chain (“γc”), a protein that is shared by the receptors for at least six interleukins. These interleukins and their receptors are critical for the development and differentiation of immune cells. The gene coding for γc is known as IL-2 receptor gamma, or IL2RG. Because IL2RG is located on the X-chromosome, XSCID is inherited in an X-linked recessive pattern, resulting in almost all patients being male.

About Mustang Bio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of chimeric antigen receptor T cell (CAR T) therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

About Minaris Regenerative Medicine

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in the US, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. Minaris Regenerative Medicine is wholly owned by Showa Denko Materials Co., Ltd. For more information, please visit www.rm.minaris.com.

Forward‐Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Minaris Regenerative Medicine Contact:

Luc St-Onge, Ph.D.
Global Head of Sales and Marketing
Minaris Regenerative Medicine GmbH

E-Mail: [email protected]
Phone: +49 (0)89 700 9608-0

Mustang Bio Contacts:

Jaclyn Jaffe and William Begien
Mustang Bio, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
[email protected]

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
[email protected]

MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it has entered into a definitive agreement with a healthcare-focused institutional investor for the purchase and sale of an aggregate of 10,126,583 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to an aggregate of 10,126,583 shares of common stock at a purchase price of $1.185 per share (or $1.175 per prefunded warrant) and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.20 per share, are exercisable immediately, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about November 25, 2020, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to Baudax Bio from the offering are expected to be approximately $12 million. In addition, in the event the warrants are exercised in full for cash, Baudax Bio expects to receive approximately $12.15 million in additional gross proceeds. However, there is no assurance that all or any portion of the warrants will be exercised prior to their expiration. Baudax Bio currently intends to use the net proceeds from the offering for the commercialization of ANJESO®, pipeline development activities and general corporate purposes.

The securities described above are being offered by Baudax Bio pursuant to a “shelf” registration statement on Form S-3 (File No. 333-243488) filed with the Securities and Exchange Commission (SEC) on August 10, 2020 and declared effective on October 2, 2020. The offering of the securities described herein will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC.  Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996, or email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About ANJESO®

ANJESO (meloxicam) injection is a proprietary, long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis. ANJESO was launched in the U.S. in June 2020 following its approval by the Food and Drug Administration in February 2020. ANJESO is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. Because of the delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required. ANJESO is supported by two pivotal Phase III clinical efficacy trials, a large double-blind, placebo-controlled Phase III safety trial and four Phase II clinical efficacy trials, as well as other safety studies. As a non-opioid, Baudax Bio believes ANJESO has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential, while maintaining meaningful analgesic effects for relief of pain. ANJESO was designed using the NanoCrystal® platform, a technology that enables enhanced bioavailability of poorly water-soluble drug compounds. NanoCrystal® is a registered trademark of Alkermes Pharma Ireland Limited (APIL).

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information please visit www.baudaxbio.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are subject to risks and uncertainties including, among other things, the completion of the registered direct offering, the satisfaction of customary closing conditions related to the registered direct offering and the intended use of proceeds from the registered direct offering, the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, Baudax Bio’s ability to maintain regulatory approval for ANJESO, Baudax Bio’s ability to successfully commercialize ANJESO; the acceptance of ANJESO by the medical community, including physicians, patients, health care providers and hospital formularies; Baudax Bio’s ability and that of Baudax Bio’s third party manufacturers to successfully scale-up our commercial manufacturing process for ANJESO, Baudax Bio’s ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO, Baudax Bio’s ability to raise future financing for continued product development, payment of milestones and ANJESO commercialization, Baudax Bio’s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio’s ability to comply with the financial and other covenants under its credit facility, Baudax Bio’s ability to manage costs and execute on our operational and budget plans, the accuracy of Baudax Bio’s estimates of the potential market for ANJESO, Baudax Bio’s ability to achieve its financial goals; and Baudax Bio’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results included in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law.

CONTACT:   

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
[email protected] 
[email protected]   

Baudax Bio, Inc.
Ryan D. Lake
(484) 395-2436
[email protected]

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
[email protected] 

SAINT PETERSBURG, FL, Nov. 23, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Energy and Water Development Corp. (OTC: EAWD) announces that it signed a Letter of Intent (LOI) to acquire a prolific 16,000 sq. ft. area near the Port of Hamburg to become its new branch in Hamburg, Germany. The property’s location is ideal as a key transportation hub. The German property is situated in a region where EAWD has a comparative advantage of engineering resources and expertise readily available to rapidly build its first CO2-free Assembling Manufactory.

EAWD recently signed several sales agreements to deliver Solar Powered Atmosphere Water Generation Systems (SPAWGs). This European CO2-free assembling manufactory is anticipated to satisfy yearly production of at least 3000 SPAWGs for worldwide export. The technological innovation of these systems is extraordinary and game changing in that they generate their own energy and water supply. 

CEO Ralph Hofmeier stated, “Despite challenges to accelerate our timeline to deliver meaningful progress due to Covid-19, we are now on a direct trajectory for sustainable production at an ideal site. We remain excited about our prospects and plans to deliver efficient CO2 Free production of the innovative, industrial size Solar Powered Atmosphere Water Generation Systems.” 

About Energy and Water Development Corp.

Energy and Water Development Corp. (“EAWD”) is a green-tech engineering solutions company focused on delivering water and energy to extreme environments. The Company offers design, construction, maintenance, and specialty consulting services to private companies, government entities and non-government organizations (NGOs).  EAWD builds water and energy systems out of already-existing, proven technologies, utilizing their technical know-how to customize solutions to their clients’ needs. Website: www.eawctechnologies.com

Forward-Looking Statements

This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings.

Contact Information:

Energy and Water Development Corp. 
Irma Velazquez, Chief Operating Officer 
Email: [email protected]
Tel. +1 347 871 8927

• Studies reinforce
  clonoSEQ
  as standard of care in
  minimal residual disease (MRD)
  across eight disease states
  
  
• Real-world evidence shows treatment decisions
  based on precise MRD measurement
  directly correlate with improved patient outcomes and cost savings
  

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, together with its collaborators will present data from more than 35 abstracts studying the use of Adaptive’s clonoSEQ^® Assay for minimal residual disease (MRD) assessment at the American Society of Hematology (ASH) virtual 62^nd Annual Meeting and Exposition, December 5-8. clonoSEQ is the first and only U.S. Food and Drug Administration (FDA)-cleared assay for MRD assessment in chronic lymphocytic leukemia (CLL), multiple myeloma and B-cell acute lymphoblastic leukemia (B-ALL) and is widely available to clinicians and patients across the U.S.

“We are thrilled to see so many investigators presenting clonoSEQ data at ASH this year, among the more than 300 ASH studies highlighting MRD data, significantly growing the body of evidence validating this tool as a critical measure of patient outcomes,” said Lance Baldo, MD, Chief Medical Officer of Adaptive Biotechnologies. “As innovation continues for the treatment of blood cancers with novel and highly targeted therapies that create deep and durable responses for patients, we see clinicians increasingly utilizing clonoSEQ to help guide day-to-day patient care.”

Assessment of MRD is a way to directly detect and quantify remaining disease, even in the absence of symptoms, across a spectrum of blood cancers. A patient’s MRD status gives clinicians timely information about how a patient may be responding to treatment, so patients and providers can be in control when it comes to managing their disease and treatment decisions.

clonoSEQ, the first clinical application of Adaptive’s immune medicine platform, will be featured in 14 oral presentations and 23 posters at ASH. Data on clinical and research utility from studies, as well as findings based on real-world experience, will be presented across a range of cancers including multiple myeloma, ALL, CLL and non-Hodgkin’s lymphoma (NHL). These new data show a correlation between clonoSEQ MRD results and improved blood cancer patient outcomes, enhanced clinical decision-making, and potential savings to the healthcare system.

Additional data at ASH this year will highlight Adaptive’s immune profiling research tool, immunoSEQ^®, to quantitatively assess the immune response to novel therapies in development.

Key presentations include:

Abstract	Title	Presentation Timing
Oral Presentations
Acute Lymphoblastic Leukemia
583	Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes	Monday, December 7, 2020: 9:15 AM
Chronic Lymphocytic Leukemia
127	Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial	Saturday, December 5, 2020: 10:30 AM
544	Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	Monday, December 7, 2020: 7:30 AM
546	Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients	Monday, December 7, 2020: 8:00 AM
Diffuse Large B-Cell Lymphoma
531	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma	Monday, December 7, 2020: 7:15 AM
Graft-Versus-Host-Disease
730	TCR Repertoires in Graft-Versus-Host-Disease (GVHD)-Target Tissues Reveals Tissue Specificity of the Alloimmune Response	Monday, December 7, 2020: 1:30 PM
Lymphoma
530	Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma	Monday, December 7, 2020: 7:00 AM
Mantle Cell Lymphoma
119	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study	Saturday, December 5, 2020: 10:00 AM
Multiple Myeloma
143	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial	Saturday, December 5, 2020: 10:00 AM
722	Spatiotemporal Assessment of Immunogenomic Heterogeneity in Multiple Myeloma	Monday, December 7, 2020: 2:15 PM
Poster Presentations
Acute Lymphoblastic Leukemia
975	Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study	Saturday, December 5, 2020, 7:00 AM-3:30 PM
Cutaneous T-Cell Lymphoma
2082	Patient Characteristics of Long-Term Responders to Mogamulizumab: Results from the MAVORIC Study	Sunday, December 6, 2020, 7:00 AM-3:30 PM
Diffuse Large B-Cell Lymphoma
1450	Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma	Saturday, December 5, 2020, 7:00 AM-3:30 PM
Mantle Cell Lymphoma
3031	Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease	Monday, December 7, 2020, 7:00 AM-3:30 PM
Multiple Myeloma
1328	Improving the Definition of Response Assessment: Prognostic Value of Minimal Residual Disease Combined with PET/CT at Day 100 Post Autologous Stem Cell Transplantation in Multiple Myeloma	Saturday, December 5, 2020, 7:00 AM-3:30 PM
1592	Role of clonoSEQ®, a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma	Saturday, December 5, 2020, 7:00 AM-3:30 PM
2237	Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma	Sunday, December 6, 2020, 7:00 AM-3:30 PM
3426	Cost-Effectiveness of Implementing Clonoseq NGS-MRD Testing Using the Emory MRD Decision Protocol in Multiple Myeloma	Monday, December 7, 2020, 7:00 AM-3:30 PM
3156	Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow	Monday, December 7, 2020, 7:00 AM-3:30 PM

About the 
clonoSEQ
Assay

The clonoSEQ Assay is the first and only FDA-cleared assay for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and B-cell acute lymphoblastic leukemia (ALL). Minimal residual disease (MRD) refers to the small number of cancer cells that can stay in the body during and after treatment. clonoSEQ was initially granted De Novo designation and marketing authorization by the FDA for the detection and monitoring of MRD in patients with MM and B-ALL using DNA from bone marrow samples. In August 2020, clonoSEQ received additional clearance from the FDA to detect and monitor MRD in blood or bone marrow from patients with CLL. 

The clonoSEQ Assay leverages Adaptive’s proprietary immune medicine platform to identify and quantify specific DNA sequences found in malignant cells, allowing clinicians to assess and monitor MRD during and after treatment. The assay provides standardized, accurate and sensitive measurement of MRD that allows physicians to predict patient outcomes, assess response to therapy over time, monitor patients during remission and predict potential relapse. Clinical practice guidelines in hematological malignancies recognize that MRD status is a reliable indicator of clinical outcomes and response to therapy, and clinical outcomes have been shown to be strongly associated with MRD levels measured by the clonoSEQ Assay in patients diagnosed with CLL, MM and ALL. 

The clonoSEQ Assay is a single-site test performed at Adaptive Biotechnologies. In addition to its FDA-cleared uses, clonoSEQ is also available as a CLIA-validated laboratory developed test (LDT) service for use in other lymphoid cancers and sample types.  For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit www.clonoSEQ.com/technical-summary.

About
immunoSEQ
Assay

Adaptive’s immunoSEQ Assay helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology. The immunoSEQ Assay can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, the immunoSEQ Assay is used to ask and answer translational research questions and discover new prognostic and diagnostic signals in clinical trials. The immunoSEQ Assay provides quantitative, reproducible sequencing results along with access to powerful, easy-to-use analysis tools. The immunoSEQ Assay is for research use only and is not for use in diagnostic procedures.

About Adaptive

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.

Forward Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

MEDIA CONTACT:

Beth Keshishian
917-912-7195
[email protected] 

ADAPTIVE INVESTORS
:

Karina Calzadilla
201-396-1687

Carrie Mendivil, Gilmartin Group
[email protected]

TEMPLE CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it has updated its revenue guidance for the full year 2020 due to accelerating demand for its COVID-19 testing solutions.

The company now expects to generate at least $300 million in revenue for the full year 2020, an increase of 28% compared to previous guidance of $235 million. This updated guidance represents estimated year-over-year revenue growth of more than 800%.

“Since our Q3 earnings call on November 9th, we have seen accelerating demand for our COVID-19 tests and are raising our full year revenue guidance to reflect this significant increase,” said Paul Kim, Chief Financial Officer of Fulgent Genetics. “As COVID-19 cases continue to rise across the country, we expect to see increasing demand for testing through the balance of the year. We believe we remain well positioned to meet this demand with our ample resources and capacity to run more than 60,000 tests per day.”

About
Fulgent Genetics

Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) – based tests. The company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: anticipated future revenue and guidance; evaluations and judgements regarding demand for the company’s testing services, including its COVID-19 testing services, evaluations and judgements regarding the company’s resources and its ability to meet any increasing demand for testing services and statements regarding the company’s ability to continue to grow its business.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemic’s effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the company’s tests, including its newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The company’s reports filed with the U.S. Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release.

Investor Relations Contact
s
:

The Blueshirt Group
Nicole Borsje, 415-217-2633; [email protected]

DUBLIN, Ireland, Nov. 23, 2020 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that members of the Avadel management team will present at both the 32nd Annual Piper Sandler Virtual Healthcare Conference and the 3rd Annual Evercore ISI HealthCONx Conference that are being held in December 2020.

Event:	32nd Annual Piper Sandler Virtual Healthcare Conference
Date:	December 1st – 3rd
Webcast:	A webcast presentation will be available via the Piper Sandler conference site (click here) from November 23rd to December 3rd. In addition, the webcast will be posted on Avadel’s website, www.avadel.com, for 90 days from being made available.
Event:	3rd Annual Evercore ISI HealthCONx Conference
Date:	Thursday, December 3rd
Time:	9:15 a.m. ET
Webcast:	A webcast will be available at (click here), as well as on the “Investors” section of the Company’s website at www.avadel.com. A replay of the webcast will be available on Avadel’s website for 90 days following the presentation.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and FDA approval of FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy. For more information, please visit www.avadel.com.

Contacts:

	Tom McHugh
	Chief Financial Officer
	Phone: (636) 449-1843
	Email: [email protected]
	Tim McCarthy
	LifeSci Advisors, LLC
	Phone: (212) 915-2564
	Email: [email protected]

 

PITTSBURGH, Nov. 23, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the 32nd Annual Piper Sandler Virtual Healthcare Conference taking place between December 1-3, 2020, as well as in a panel discussion at the 3rd Annual Evercore ISI HealthCONx Conference, which is also being held from December 1-3, 2020.

A webcast of the Piper Sandler fireside chat will be available on the Piper Sandler conference site from November 23rd to December 3rd. In addition, this webcast will also be available on the NeuBase website, www.neubasetherapeutics.com, for 90 days following the recording of the presentation.

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines. NeuBase’s designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
OP: (617) 430-7576

NeuBase Media Contact:

Cait Williamson, Ph.D.
LifeSci Public Relations
[email protected]
OP: (646) 751-4366

 

LONDON, Nov. 23, 2020 (GLOBE NEWSWIRE) — SNOMED International has released a series of videos that demonstrate the value that a healthcare system is deriving from implementing and using SNOMED CT, the world’s most comprehensive clinical terminology.

The first chapter of the SNOMED CT Value Series, which focuses on New Zealand’s Canterbury District Health Board (CDHB), highlights the advances the organization has made in realizing its vision of a connected, integrated system that supports the country’s Healthy Ageing strategy and enables it to better serve its population. Acting Executive Director Planning, Funding and Decision Support, Ralph La Salle offers that “an integrated health system is essential for the health outcomes of the Canterbury population and quality data with thorough analysis leads to shared clinical insights and new ways of working collectively to optimise this integration.”

Carolyn Gullery, who at the time of filming was the Executive Director, Planning, Funding and Decision Support for the CDHB, said New Zealand’s commitment to becoming a SNOMED International Member in 2007 was the beginning of a positive change for a healthcare system that was, like so many others across the globe, under extreme financial and performance-related pressure. She explains that in 2007, while its primary care system was thriving, its hospital system was struggling. Canterbury needed a better picture of its current situation and a way to predict the future needs of its 578,000 residents.

Harnessing the power of data analytics

Key to that goal, she noted, was the ability to use data and analytics to understand why people were ending up in the health system, who they were and how to intervene more effectively to reduce the demand on the system and provide better care for patients. By using SNOMED CT as part of its core infrastructure, and its Healthcare Analytics Solution (HCAS), a software tool that applies natural language processing to the unstructured text-based data in a clinical record, the health boards were able to code their existing data to SNOMED CT and then demonstrate to clinicians the power of using those codes to analyze that data. It is estimated that approximately 80 percent of health data is unstructured, and can represent text, photos, X-rays, voice/video recordings, slides and emails, among other types of health data.

By building a series of systems that act as an integrated health platform, CDHB managed to use the same number of beds in 2019 as it did in 2007 for a population that over 12 years had grown by 80,000. Canterbury representatives also observed a 30 percent lower emergency department use and a 30 percent lower acute medical admission rate than the national average, meaning New Zealanders are less likely to end up in the hospital in Canterbury than in any other part of the country.

R
educing manual labor for clinicians

According to Dr. Nigel Gilchrist, a Canterbury physician, the organization had also struggled to identify vertebral spine fractures and identify patients who may not have received care for those fractures. By using SNOMED CT to search 13,000 X-ray reports as part of a pilot project involving West Coast DHB patients, the organization found that one-third of relevant patients had been treated, another third had not, and the remaining third had been misclassified.

“We now identify over 200 new vertebral fractures every month,” he explained. “SNOMED CT has enabled us to identify specific case mixes that would otherwise take someone a long time to do manually.” In fact, the organization saved more than a year of a clinician’s time.

Interoperability across platforms

Another benefit of using SNOMED CT is its interoperability across the healthcare district’s best-of-breed applications. “We need to be sure we’re speaking the same language when we use data, and if we move it around, it’s got to mean the same thing in one place as in another,” said Dr. Saxon Connor, a Canterbury physician.

Other Canterbury clinicians say they are most excited by SNOMED CT’s ability to help two different clinical tools – an electronic medical record system and a pathways tool – talk to each other via a SNOMED CT code linked to diagnoses, and by the ability to search for pathways and find hierarchies.

“In the past, we had to go through our pathways manually and put keywords on them so people could find them, and with SNOMED we get all those synonyms for free,” said Kieran Holland, Clinical Lead for New Zealand’s HealthPathways Programme, an online clinical guidance tool. “It has improved the user search experience.”

SNOMED CT: a piece of the digital health ecosystem as CDHB realizes multiple benefits

• 30 percent lower emergency department use than the national average
• 30 percent lower acute medical admission rate than the national average
• Held 2019 bed use to same numbers as in 2007 while serving a population that had grown by 80,000
• Identified vertebral fracture patients who had not received care or whose cases had been misclassified
• Saved a year of clinician time by automating previously manual processes
• Interoperable across best-of-breed system
• Ability to link clinical tools via a SNOMED code
• Ability to search for pathways and hierarchies and improved user search experience

There is more energy than ever in rolling out SNOMED CT as a key clinical information standard for an equitable New Zealand health and disability system, one that is data-driven and digitally enabled and SNOMED International’s CEO, Don Sweete, recognizes the dedication of New Zealand’s implementation efforts. “Canterbury is a great example of the breadth of maturity that SNOMED CT offers from data coding, data analysis, and ultimately the ability to apply artificial intelligence to already structured SNOMED CT data. It’s an end to end example of the benefit of SNOMED CT.”

New Zealand’s focus over the next few years is on primary and community care, where users are migrating their systems from Read Codes to SNOMED CT as they introduce new models of care and supporting software.

Watch the Value Series to learn more about SNOMED CT and New Zealand, a founding SNOMED International Member represented by the Ministry of Health Manatū Hauora.

About SNOMED International

SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world’s most comprehensive healthcare terminology product.  We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms.  This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community.  SNOMED International is the trading name of the International Health Terminology Standards Development Organisation. Learn More…

Kelly Kuru
Chief Communications Officer
SNOMED International
[email protected]